[go: up one dir, main page]

WO2024233999A3 - Anxiolytic therapy - Google Patents

Anxiolytic therapy Download PDF

Info

Publication number
WO2024233999A3
WO2024233999A3 PCT/US2024/029096 US2024029096W WO2024233999A3 WO 2024233999 A3 WO2024233999 A3 WO 2024233999A3 US 2024029096 W US2024029096 W US 2024029096W WO 2024233999 A3 WO2024233999 A3 WO 2024233999A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
anxiolytic
anxiolytic therapy
therapy
asprosin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/029096
Other languages
French (fr)
Other versions
WO2024233999A2 (en
Inventor
Atul Chopra
Bijoya BASU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
University Hospitals Cleveland Medical Center
Original Assignee
Case Western Reserve University
University Hospitals Cleveland Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University, University Hospitals Cleveland Medical Center filed Critical Case Western Reserve University
Priority to AU2024269420A priority Critical patent/AU2024269420A1/en
Publication of WO2024233999A2 publication Critical patent/WO2024233999A2/en
Publication of WO2024233999A3 publication Critical patent/WO2024233999A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method of treating an anxiety disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of an anxiolytic agent that inhibits asprosin mediated protein tyrosine phosphatase receptor type δ (PTPRD) signaling or activity.
PCT/US2024/029096 2023-05-11 2024-05-13 Anxiolytic therapy Pending WO2024233999A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024269420A AU2024269420A1 (en) 2023-05-11 2024-05-13 Anxiolytic therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363501474P 2023-05-11 2023-05-11
US63/501,474 2023-05-11

Publications (2)

Publication Number Publication Date
WO2024233999A2 WO2024233999A2 (en) 2024-11-14
WO2024233999A3 true WO2024233999A3 (en) 2025-04-24

Family

ID=93431237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/029096 Pending WO2024233999A2 (en) 2023-05-11 2024-05-13 Anxiolytic therapy

Country Status (2)

Country Link
AU (1) AU2024269420A1 (en)
WO (1) WO2024233999A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100216653A1 (en) * 2007-10-05 2010-08-26 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V Use of polymorphisms in the tmem132d gene in the prediction and treatment of anxiety disorders
US20150030602A1 (en) * 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
WO2023023588A2 (en) * 2021-08-18 2023-02-23 Case Western Reserve University Methods and compositions of inhibiting asprosin mediated orexigenesis and/or glucogenesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100216653A1 (en) * 2007-10-05 2010-08-26 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V Use of polymorphisms in the tmem132d gene in the prediction and treatment of anxiety disorders
US20150030602A1 (en) * 2011-12-23 2015-01-29 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
WO2023023588A2 (en) * 2021-08-18 2023-02-23 Case Western Reserve University Methods and compositions of inhibiting asprosin mediated orexigenesis and/or glucogenesis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HO EMILY V., WELCH AMANDA, THOMPSON SUMMER L., KNOWLES JAMES A., DULAWA STEPHANIE C.: "Mice lacking Ptprd exhibit deficits in goal-directed behavior and female-specific impairments in sensorimotor gating", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 18, no. 5, 19 May 2023 (2023-05-19), US , pages e0277446, XP093307804, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0277446 *
MISHRA ILA, DUERRSCHMID CLEMENS, KU ZHIQIANG, HE YANG, XIE WEI, SILVA ELIZABETH SABATH, HOFFMAN JENNIFER, XIN WEI, ZHANG NINGYAN, : "Asprosin-neutralizing antibodies as a treatment for metabolic syndrome", ELIFE, ELIFE SCIENCES PUBLICATIONS LTD., GB, vol. 10, GB , XP093307713, ISSN: 2050-084X, DOI: 10.7554/eLife.63784 *
TOMITA HIDEAKI, CORNEJO FRANCISCA, ARANDA-PINO BEGOÑA, WOODARD CAMERON L., RIOSECO CONSTANZA C., NEEL BENJAMIN G., ALVAREZ ALEJAND: "The Protein Tyrosine Phosphatase Receptor Delta Regulates Developmental Neurogenesis", CELL REPORTS, ELSEVIER INC, US, vol. 30, no. 1, 1 January 2020 (2020-01-01), US , pages 215 - 228.e5, XP093307705, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2019.11.033 *
VIGGIANO ADELA; CACCIOLA GIOVANNA; WIDMER DAVID A.J.; VIGGIANO DAVIDE: "Anxiety as a neurodevelopmental disorder in a neuronal subpopulation: Evidence from gene expression data", PSYCHIATRY RESEARCH, ELSEVIER IRELAND LTD, IE, vol. 228, no. 3, 1 January 1900 (1900-01-01), IE , pages 729 - 740, XP029255716, ISSN: 0165-1781, DOI: 10.1016/j.psychres.2015.05.032 *

Also Published As

Publication number Publication date
AU2024269420A1 (en) 2025-11-27
WO2024233999A2 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
Schratzberger et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy
Pittaluga Ccl5–glutamate cross-talk in astrocyte-neuron communication in multiple sclerosis
Wolf et al. Angiotensin II as a renal growth factor.
Lambiase et al. Nerve growth factor (NGF) reduces and NGF antibody exacerbates retinal damage induced in rabbit by experimental ocular hypertension
Gouveia et al. What have we learned about the kallikrein-kinin and renin-angiotensin systems in neurological disorders?
EP1133294A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, CENTRAL NERVOUS SYSTEM INJURY AND INFLAMMATORY DISEASES
Zeng et al. Activation of protease‐activated receptor 2‐mediated signaling by mast cell tryptase modulates cytokine production in primary cultured astrocytes
WO2004084835A3 (en) Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
NO20031867L (en) Procedure for the treatment of neurological and neuropsychological disorders
MA35437B1 (en) Fusion Proteins for the Treatment of Metabolic Disorders
Pettersen et al. Autocrine activin A signalling in ovarian cancer cells regulates secretion of interleukin 6, autophagy, and cachexia
Fu et al. Tff3 is expressed in neurons and microglial cells
Bierl et al. Increased NGF proforms in aged sympathetic neurons and their targets
WO2022026902A3 (en) Chimeric proteins and methods of use for treatment of central nervous system disorders
ES531908A0 (en) A PROCEDURE FOR THE PREPARATION OF NEW INDOLONES.
Tannenberg et al. Extracellular retention of PDGF-B directs vascular remodeling in mouse hypoxia-induced pulmonary hypertension
WO2024233999A3 (en) Anxiolytic therapy
Gu et al. Sinomenine reduces iNOS expression via inhibiting the T-bet IFN-γ pathway in experimental autoimmune encephalomyelitis in rats
Corasaniti et al. HIV‐1 coat protein gp120 stimulates interleukin‐1β secretion from human neuroblastoma cells: evidence for a role in the mechanism of cell death
Lastres-Becker et al. Endotoxin preconditioning protects neurones from in vitro ischemia: role of endogenous IL-1β and TNF-α
Kunze et al. Autocrine TNF-α and IL-1β prime 6-sulfo Lac NAc+ dendritic cells for high-level production of IL-23.
WO2020225799A3 (en) A method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein
WO2003105753A3 (en) Targeted enzymes and methods of making and using targeted enzymes.
Chen et al. Divergent effects of oncostatin M on astroglioma cells: influence on cell proliferation, invasion, and expression of matrix metalloproteinases
Hernández‐Ortega et al. ERK activation and expression of neuronal cell cycle markers in the hippocampus after entorhinal cortex lesion

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24804389

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2024269420

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2024269420

Country of ref document: AU

Date of ref document: 20240513

Kind code of ref document: A